Risks and Benefits of Islet Transplantation


By: J. Chanslor

Islet transplantation offers promise, but it still shows risks of complications and loss of islet function over time.

After initiating a new islet isolation and transplant center, National Institutes of Health researchers related their experiences, sharing the islet transplant outcomes of six female type 1s, all with a history of hypoglycemia unawareness and no self-production of insulin (serum C-peptide negative).

These patients received the antirejection drugs daclizumab, sirolimus and tacrolimus-a steroid-sparing combination.

Results showed that all patients noted less frequent and less severe low blood glucose episodes, and 50 percent were insulin-free at one year after transplant. All but one showed serum C-peptide levels indicating continued islet cell insulin-production function.

Two major complications were serious intra-abdominal bleeding and partial portal vein thrombosis (blockage by blood clotting). In addition, recipients frequently developed transient mouth ulcers, diarrhea, edema (fluid retention), high blood cholesterol, weight loss, bone-marrow suppression and other symptoms.

Of the six patients, three discontinued the anti-rejection drugs, two because of intolerable toxicity, such as decreasing kidney function, while still showing islet function, and one because of loss of islet function.

-Diabetes Care, December 2003



Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.